BRISTOL MYERS SQUIBB COBMY
時価総額
$1085.5億
PER
研究開発から製造・販売まで手掛けるグローバルバイオ医薬品の最大手。がん、免疫、心血管、神経領域の革新的医薬品や抗PD-1などの免疫療法を展開。2024年にKaruna、RayzeBioを買収、ミラティを約48億ドルで買収。米国中心に製造拠点約130サイト、従業員約34,100人で43カ国に展開。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net (loss)/earnings | 4,513 | 5,260 | 2,501 | 2,580 | 2,029 | 1,631 | 4,507 | 975 | 4,947 | 3,460 | -8,995 | 7,014 | 6,345 | 8,040 | -8,933 |
| Depreciation and amortization, net | - | - | 681 | 763 | 467 | 376 | 382 | 789 | 637 | 1,746 | 10,380 | 10,686 | 10,276 | 9,760 | 9,600 |
| Deferred income taxes | 422 | 415 | -1,230 | -491 | -542 | -347 | -204 | 1,010 | 86 | -924 | 983 | -1,393 | -2,738 | -3,288 | -2,089 |
| Stock-based compensation | 193 | 161 | 154 | 191 | 213 | 235 | 205 | 199 | 221 | 441 | 779 | 583 | 457 | 518 | 507 |
| Impairment charges | - | 28 | 2,180 | 40 | 401 | 192 | 108 | 332 | 126 | 199 | 1,203 | 1,207 | 179 | 255 | 2,963 |
| Divestiture gains and royalties | - | - | - | - | - | - | - | - | - | - | - | - | 1,063 | 884 | 1,119 |
| Acquired IPRD | - | - | - | - | - | - | - | - | - | - | - | - | - | 913 | 13,373 |
| Equity investment (gains)/losses, net | - | - | - | - | - | - | - | - | - | - | - | 745 | -801 | -160 | 16 |
| Other adjustments | - | 147 | 35 | 9 | 567 | -594 | 44 | -92 | 44 | 22 | 177 | -142 | -232 | -308 | -94 |
| Receivables | 270 | 220 | -648 | 504 | 252 | 942 | 803 | 431 | 429 | -752 | 646 | 1,054 | 663 | 995 | -264 |
| Inventories | -156 | 193 | 103 | 45 | 254 | -97 | 152 | 29 | 216 | -463 | -2,672 | -13 | 69 | 751 | 486 |
| Accounts payable | 315 | 593 | -232 | 412 | -44 | -919 | 104 | 320 | -59 | 229 | 188 | 245 | 109 | 198 | 184 |
| Rebates and discounts | - | - | - | - | - | - | - | - | - | - | - | 863 | 427 | 904 | 1,484 |
| Income taxes payable | -236 | -134 | -50 | 126 | 171 | 47 | -545 | 2,597 | 162 | 907 | -2,305 | -1,063 | -1,423 | -603 | -1,260 |
| Other | -248 | 58 | 897 | 466 | 33 | -471 | -100 | 227 | -634 | -702 | -1,074 | 257 | 610 | 667 | -624 |
| Net cash provided by operating activities | 4,491 | 4,840 | 6,941 | 3,545 | 3,148 | 1,832 | 2,850 | 5,275 | 5,940 | 8,067 | 14,052 | 16,207 | 13,066 | 13,860 | 15,190 |
| Sale and maturities of marketable debt securities | - | 5,960 | 4,890 | 1,815 | 4,095 | 2,794 | 4,809 | 6,412 | 2,379 | 3,809 | 6,280 | 4,196 | 6,411 | 733 | 1,122 |
| Purchase of marketable debt securities | 5,823 | 6,819 | 3,607 | 1,859 | 5,719 | 3,143 | 3,089 | 5,437 | 2,305 | 3,961 | 4,172 | 5,478 | 3,592 | 1,774 | 769 |
| Proceeds from sales of equity investments | - | - | - | - | - | - | - | - | - | - | - | - | - | 215 | 265 |
| Capital expenditures | 424 | 367 | 548 | 537 | 526 | 820 | 1,215 | 1,055 | 951 | 836 | 753 | 973 | 1,118 | 1,209 | 1,248 |
| Divestiture and other proceeds | - | - | - | - | - | - | - | - | - | - | - | - | 1,305 | 909 | 1,099 |
| Acquisition and other payments, net of cash acquired | 829 | 360 | 7,530 | - | 219 | 1,111 | 359 | 708 | 1,246 | 24,634 | 13,084 | 1,610 | 4,286 | 1,169 | 21,821 |
| Net cash used in investing activities | -3,812 | -1,437 | -6,727 | -572 | 1,216 | -1,572 | 1,480 | -66 | -874 | -9,770 | -10,859 | -538 | -1,062 | -2,295 | -21,352 |
| Proceeds from Issuance of Commercial Paper | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,987 |
| Repayments of short-term debt obligations | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3,000 |
| Proceeds from Other Short-Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 99 |
| Proceeds from issuance of long-term debt | 6 | - | 1,950 | 1,489 | - | 1,268 | - | 1,488 | - | 26,778 | 6,945 | - | 5,926 | 4,455 | 12,883 |
| Repayments of long-term debt | 936 | 78 | 2,108 | 597 | 676 | 1,957 | 15 | 1,224 | 5 | 9,256 | 2,750 | 6,022 | 11,431 | 3,879 | 2,873 |
| Repurchase of common stock | 576 | 1,221 | 2,403 | 433 | - | - | 231 | 2,469 | 320 | 7,300 | 1,546 | 6,287 | 8,001 | 5,155 | - |
| Dividends | 2,202 | 2,254 | 2,286 | 2,309 | 2,398 | 2,477 | 2,547 | 2,577 | 2,613 | 2,679 | 4,075 | 4,396 | 4,634 | 4,744 | 4,863 |
| Stock option proceeds and other, net | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -106 |
| Net cash provided by/(used in) financing activities | -3,343 | -2,657 | -4,333 | -1,068 | -2,437 | -3,351 | -2,445 | -4,077 | -3,535 | 7,621 | -1,151 | -16,224 | -16,962 | -9,416 | 5,127 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | - | - | -9 | 111 | -102 | -33 | 45 | -137 |
| (Decrease)/increase in cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | - | - | 5,909 | 2,153 | -657 | -4,991 | 2,194 | -1,172 |